Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

Exclusion criteria

• . Creatinine clearance below the contraindication limit in the locally approved prescribing information.
• . Serum creatinine level \> 1.5 x ULN (upper limit of normal)
• . AST (SGOT) /ALT (SGPT) \> 5 x ULN, unless LIC confirmed as \>10 mg Fe/dw within 6 months prior to screening visit.
• . Significant proteinuria as indicated by a urinary protein/creatinine ratio \> 0.5 mg/mg in a non-first void urine sample.
• . Patients with significant impaired gastrointestinal (GI) function or GI disease that might significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
• . Clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive).
• . Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing any of the treatment options or patients unwilling or unable to comply with the protocol
• . Patients with a known history of HIV seropositivity (Elisa or Western blot).